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Figure 1. Pain and Symptoms Pre-, During, and Post-Collection in Older
Related Donors
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experience grade 2-4 pain (62 vs. 28%; p¼0.001) and grade 2-
4 symptoms (35 vs. 14%; p¼0.01) on day 5 of G-CSF. Female
donors showed lower rates of return to baseline symptom
levels at one month (72 vs. 85%, female vs. male; p¼0.028).
Race and ages 61-65, 66-70, and 71+ had no effect.
Conclusions: Related donors over age 60 have high baseline
rates of pain and other symptoms. Their rate of any grade
pain is lower but grade 3-4 pain is higher on the day of
collection and recovery at one month is slower than noted in
past studies of younger unrelated donors. Donors with
baseline pain are at risk of experiencing higher levels of pain
and symptoms during the collection process, and women
recovermore slowly thanmen. Additional analyses including
baseline organ-speciﬁc comorbidities and multivariable
analysis of risk will be presented with these data.
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Background: Female donors for male recipients worsens
outcome of allogeneic haematopoietic stem cell trans-
plantation (HSCT). We wanted to ﬁnd out whether a maleHLA-matched unrelated donor (MUD, 8/8, n¼2,014)might be
an alternative to a female HLA-identical sibling donor
(n¼2,656) for males with acute leukaemia.
Methods: A retrospective analysis from the Acute Leukemia
Working Party of the European Group for Blood and Marrow
Transplantation.
Results: The relative risk (RR) of acute GVHD of grades IIeIV
was increased in the MUD group with acute myeloid
leukaemia (AML) (RR 1.47, p<0.001) and acute lymphoblastic
leukaemia (ALL) (RR 1.76, p<0.001). There was no difference
in incidence of chronic GVHD and non-relapse mortality
between the two groups. Probability of relapse was lower in
the MUD group than in the sibling group in ALL patients (HR
0.75, p¼0.04) but not in AML patients (HR 0.89, p¼0.17).
Survival was not different between the groups. Leukaemia-
free survival (LFS) was also similar in the sibling and MUD
groups in patients with AML (HR 1.01, p¼0.81) or ALL (HR
0.93, p¼0.45). Factors signiﬁcantly associated with reduced
LFS included active disease, poor cytogenetics, age, year of
HSCT, reduced-intensity conditioning, and the use of anti-
thymocyte globulin.
Conclusion: Male patients who received grafts from male
MUDs had an increased incidence of acute GVHD and the
same LFS as when using HLA-identical female donors.32
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We have previously reported a lower than expected inci-
dence of acute GVHD in recipients of sibling donor allogeneic
HSC transplants mobilized with GM-CSF alone (Devine et al.
BMT 2005). However, the use of GM-CSF as a single agent for
stem cell mobilization has been limited by a high (w30%)
incidence of failure to mobilize and collect adequate stem
cell numbers in a single apheresis procedure. Based on
observed synergy between GM-CSF and plerixafor for HSC
mobilization in mice, we hypothesized that this combination
in humansmight overcome the low stem cell yields observed
with either agent alone and result in a PBSC product enriched
in Tregs and MDSCs that could reduce GvHD after transplant.
The efﬁcacy of GM-CSF (initially given 10 mcg/kg SC daily x 5
e 6 days but reduced to 5mcg/kg daily secondary to toxicity),
and plerixafor (320 mcg/kg IV daily starting on day 5) was
tested in a phase II trial.
The primary objective of this trial was reduction in the day 1
mobilization failure rate from 33% to <10%. We planned to
enroll 17 donor recipient pairs. Donors failing to reach 20L
apheresis volume were replaced. To date 22 donors (4 at
10mcg/kg GM-CSF and 18 at 5mcg/kg GM-CSF) have been
mobilized and 19 recipients transplanted. Initial mobilization
with GM-CSF 10mcg/kg was complicated by catheter and IV
tubing-associated thrombosis at the time of apheresis in 4/4
donors. Because of this, GM-CSF dose was reduced to 5 mcg/
kg SC daily x 5e6 days. Since this dose reduction, access
complications have occurred in 3/18 donors that precluded a
full 20 L apheresis. There has been no grade 3e4 adverse
events related to mobilization.
Figure.
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volume on day 1 demonstrated a failure to collect 2x106
CD34/kg recipient weight in 2/15 donors (13.3%). The mean
CD34/Kg recipient weight collected from these donors was
3.97 x 106 CD34/Kg. No donor regardless of day one
apheresis volume failed to reach this goal after two days of
apheresis.
All recipients engrafted. The median time to neutrophil
engraftment was 13 days (range 11 - 22 days), and median
time to platelet engraftment >50K was 24 days (range 15 -
106). 14/18 (78%) recipients had 100% donor chimerism at
day 30 post transplant. Of the 14 evaluable recipients
receiving mobilized products from donors mobilized with
5mcg/kg GM-CSF+plerixafor, the incidence of grades IIeIV
and III-IV acute GvHD was 35.7% and 21.2%. Of all evaluable
recipients (n¼18) treated on study, the incidence of grades II-
IV and III-IV acute GvHD were 44% and 22.2%. The incidence
of cGvHD for all recipients surviving past 100 days (n ¼ 13)
was 61.5%. CMV viremia occurred in 10/15 (66.6%) of re-
cipients and CMV disease was identiﬁed or suspected in 5/15
(33.3%).
GM-CSF at 5mcg/kg combined with IV plerixafor is a feasible
combination to overcome low apheresis CD34 yields
observed with either agent alone. Phenotypic and functional
studies of cellular graft content are ongoing.33
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Detected pathogens in BAL samples
IPS cases (N¼69), N
(%)
Control (N¼2l), N
(%)
Pathogenicity
in lung
Detected
pathogens
Any High
pathogen
load*
Any High
pathogen
load*
Known CMV 8 (12) 0 7 (33) 0
RSV 2 (3) 1 (1) 0 0
PIV 2 (3) 0 0 0
HMPV 2 (3) 2 (3) 0 0
Aspergillus 8 (12) 1 (1) 3 (14) 0
Unknown HHV6 20 (29) 4 (6) 1 (5) 0
HRV 8 (12) 6 (9) 1 (5) 0
Kl 3 (4) 1 (1) 5 (24) 0
WU 1 (1) 0 0 0
CoV 0 0 1 (5) 1 (5)
HSV 2 (3) 0 0 0
EBV 1 (1) 0 2 (10) 0
BK 3 (4) 0 0 0
The values indicate the total number of patients (percentage of detected
patients).
* High load: >100,000 copies/ml, <32 cycle threshold (HRV) or co-detection
of a GM in serum.Center Hospital, Tokyo, Japan; 9Laboratory Medicine,
University of Washington, Seattle, WA; 10Vaccine and Infectious
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Background: Idiopathic pneumonia syndrome (IPS) is
diagnosed by clinical/radiographic presentation and the
exclusion of infection. However, molecular diagnostic
methods may allow cases previously classiﬁed as idiopathic
to be linked to an infectious agent. We applied a broad panel
of currently available molecular tests and pathogen discov-
ery methods to patients with IPS and correlated pathogen
detection with outcome.
Methods: Frozen bronchoalveolar lavage (BAL) samples
from 69 HCT patients with IPS diagnosed from 1992 to
2006 were tested by Q-PCR for Legionella, M. pneumoniae,
C. pneumoniae, HSV, VZV, EBV, CMV, HHV-6, polyomavirus
(BK, JC, WU, KI), parvovirus B19, RSV, PIV, Inﬂuenza, HMPV,
ADV, HRV, CoVs, HBoV, Enterovirus and Parechovirus, and
for aspergillus GM (aGM). Research BALs obtained between
day 35 and 50 from 21 asymptomatic HCT patients served
as controls. Pathogens were categorized by quantity and
known/unknown pathogenicity; the association with
overall mortality was analyzed using Cox regression
models.
Results: Among 69 HCT patients with IPS (time from HCT to
BAL: median 22 days, range 4e119), 39 (57%) had a pathogen
detected, compared to 11 out of 21 controls (52%); high
pathogen load was detected in 19% and 5%, respectively
(Table). The most frequent pathogens were HHV-6 and HRV;
CMV low-level shedding was also detected. Among the pa-
tients with IPS, the presence of a pathogen was associated
with higher mortality in multivariate models (HR, 1.92;
p¼0.03; adjusted for donor type, steroid use, and diffuse
alveolar hemorrhage); neither pathogenicity category
(Figure) nor pathogen loadwere signiﬁcantly associatedwith
mortality.
Conclusions: A signiﬁcant number of pathogens were
detected in patients with IPS, and pathogen detection was
associated with increased mortality. The increased mortality
could be due to lack of speciﬁc treatment and/or use of cor-
ticosteroids. Known pathogens (aspergillus, RSV, PIV, HMPV)
can now be readily detected by multiplex PCR and the aGM
assay. The interpretation of the detection of pathogens of
unknown signiﬁcance (HHV-6, HRV) is more difﬁcult, but
mortality was similar to that of known pathogens. Overall,
our data suggest that expanded infection detection panels
may re-classify a signiﬁcant number of IPS cases as infectious
pneumonia.
